Of these, 4 have developed venous or arterial thrombotic complications
Here's the realistic timeline: Phase 3 trials (AMAZE program): - AMAZE 1 (obesity) started February 2026, enrolling ~1,150 participants - Primary completion estimated: June 2029 - Phase 3 in T2D also being planned following the ADA 2026 data US FDA approval (projected): Q4 2030 at the earliest (GlobalData estimate) EU EMA approval (projected): Q1 2031 at the earliest Bulgaria and Eastern Europe: Typically 612 months after EMA approval for market access, depending on national reimbursement negotiations
Therefore, glucagon acts not only to increase glucose production but also to induce lipolysis, fatty acid oxidation, ketogenesis, increase thermogenesis and energy expenditure, bile acid synthesis, and finally induce satiation and reduce food intake [22, 23]
You can pause or stop at any time
A clear understanding starts with a few practical questions
But within that is a great deal of variety or heterogeneity, and we don't really know why